Alnylam Pharmaceuticals Inc
LSE:0HD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
C
|
Constellation Software Inc
DUS:W9C
|
CA |
|
Valeo Pharma Inc
F:VP2
|
CA |
|
F
|
Fomento de Construcciones y Contratas SA
DUS:FCC
|
ES |
|
M
|
MTU Aero Engines AG
F:MTX
|
DE |
|
S
|
Sogefi SpA
MIL:SO
|
IT |
|
A
|
Australia and New Zealand Banking Group Ltd
F:ANB
|
AU |
|
Cartesian Therapeutics Inc
F:1S70
|
US |
|
NexPoint Residential Trust Inc
F:5O4
|
US |
|
F
|
First Solar Inc
XBER:F3A
|
US |
|
Concurrent Technologies PLC
LSE:CNC
|
UK |
|
Danakali Ltd
ASX:DNK
|
AU |
|
A
|
Argo Blockchain PLC
OTC:ARBKF
|
UK |
|
X
|
Xenon Pharmaceuticals Inc
SWB:XP0
|
CA |
|
G
|
Grupo Simec SAB de CV
AMEX:SIM
|
MX |
|
Neuropace Inc
NASDAQ:NPCE
|
US |
|
E
|
Extreme Networks Inc
F:EXM
|
US |
|
C
|
Chime Financial Inc
NASDAQ:CHYM
|
US |
|
Bid Corporation Ltd
OTC:BDDDY
|
ZA |
|
Straumann Holding AG
F:QS5
|
CH |
|
Emmi AG
F:FV6
|
CH |
|
H
|
Hain Celestial Group Inc
F:HF1
|
US |
|
Argo Blockchain PLC
F:0XP
|
UK |
|
Hotel Chocolat Group PLC
F:H0C
|
UK |
Wall St Price Targets
0HD2 Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0HD2 is 454.33 USD with a low forecast of 239.16 USD and a high forecast of 596.28 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0HD2's stock price target?
Price Target
454.33
USD
According to Wall Street analysts, the average 1-year price target for 0HD2 is 454.33 USD with a low forecast of 239.16 USD and a high forecast of 596.28 USD.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
19%
The compound annual growth rate for Gross Profit over the next 8 years is 19%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
37%
The compound annual growth rate for Operating Income over the next 8 years is 37%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
93%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
40%
The compound annual growth rate for Net Income over the next 8 years is 40%.
